Detection method of related substances of teprenone
By using high-performance liquid chromatography using thycosylsilane bonded silica gel filler and specific mobile phases, the problem of difficult detection of epoxy impurities and isomer impurities in teprene was solved, and the teprene was achieved. The efficient and accurate detection of relevant substances reduces cost and time.
Patent Information
- Application Number
- CN202411398266.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-09
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art cannot effectively detect 7 epoxy impurities and 2 monocis isomer impurities in teprene, especially 5E, 9E, 13Z and 5E, 9Z, 13E, which are difficult to separate, resulting in defects in the detection method.
The volume ratio of the chromatographic column using thycosylsilane bonded silica gel as filler and the mobile phase is [acetonitrile-n-butanol (2-3:0.5-1)]-water (65-80:20-35). Combined with high performance liquid chromatography, epoxy impurities and isomer impurities can be detected and separated simultaneously, including 5E, 9E, 13Z and 5E, 9Z, 13E, and distinguished from tepredone active ingredients.
It improves detection efficiency, accuracy and sensitivity, reduces detection costs, and shortens the detection time while ensuring high resolution, achieving accurate identification and quantification of teprene-related substances.
Smart Images

Figure CN119086779A_ABST
Abstract
Description
Technical Field
[0001] The present specification relates to the field of drug detection technology, and in particular to a method for detecting related substances of teprenone in teprenone raw materials and teprenone preparations. Background Art
[0002] Teprenone is a gastric mucosal protective drug that can be used to treat acute gastritis, chronic gastritis, acute exacerbation of gastric mucosal lesions (erosion, bleeding, flushing, edema) and gastric ulcers. The teprenone compound is called 6,10,14,18-tetramethyl-5,9,13,17-nonadecatetraen-2-one, and its molecular formula is C 23 H 38 O, is a mixture of mono-cis isomers (5Z, 9E, 13E) and all-trans isomers (5E, 9E, 13E), and its chemical structures are shown in Formula I and Formula II respectively:
[0003] The applicant found in the study that teprenone contains multiple double bonds in its structure. The main degradation pathway is the oxidation of the double bonds on the carbon chain to produce epoxidized teprenone. Teprenone may produce 7 oxidative degradation impurities, namely epoxide impurities 1-7:
[0004] Up to now, there is no prior art that discloses the detection of epoxy impurities, let alone the detection of the above-mentioned 7 types of epoxy impurities.
[0005] In addition, it can be seen from the chemical structural formula I and formula II of teprenone that teprenone has 8 geometric isomers, and the remaining 6 isomers except the active ingredients 5Z, 9E, 13E and 5E, 9E, 13E are all impurities. The names, codes and chemical structures of the 6 isomer impurities can be found in Table 1 of CN116539765B. The isomer impurities of teprenone and the aforementioned epoxy impurities can be collectively referred to as "related substances". Among the six isomeric impurities of teprenone, 5Z, 9Z, 13Z, 5Z, 9E, 13Z, 5E, 9Z, 13Z and 5Z, 9Z, 13E can be separated and detected by the national drug standards (standard numbers JX20050119 and YBH05822009), but the above national drug standards cannot separate and detect the other two isomeric impurities (5E, 9E, 13Z) and (5E, 9Z, 13E). Patent CN116539765B discloses the use of high performance liquid chromatography for detection, but the two mono-cis isomeric impurities (5E, 9E, 13Z) and (5E, 9Z, 13E) are difficult to separate from each other and basically overlap into one peak, so they can only be detected by combined detection (from paragraphs 0084-0087 of the specification of CN116539765B).
[0006] It can be seen that there is no public related detection method for separating and detecting the seven epoxy impurities and two mono-cis isomer impurities (5E, 9E, 13Z) and (5E, 9Z, 13E) of teprenone. Summary of the invention
[0007] In view of this, the object of the present disclosure is to provide a method for detecting related substances of teprenone in teprenone bulk drugs and teprenone preparations. The first aspect of the present disclosure is to provide a method for detecting epoxy impurities of teprenone, which can distinguish epoxy impurities from other impurities. The second aspect of the present disclosure is to provide a method for detecting two mono-cis isomer impurities (5E, 9E, 13Z) and (5E, 9Z, 13E). The third aspect of the present disclosure is to provide a method for detecting two mono-cis isomer impurities (5E, 9E, 13Z) and (5E, 9Z, 13E) from the active ingredients of teprenone 5Z, 9E, 13E and 5E, 9E, 13E. In some embodiments of the present disclosure, by using a chromatographic column with triacontylsilane bonded silica gel as a filler and a mobile phase with a volume ratio of [acetonitrile-n-butanol (2-3:0.5-1)]-water (65-80:20-35), epoxy impurities and isomeric impurities can be detected simultaneously, and two isomeric impurities (5E, 9E, 13Z) and (5E, 9Z, 13E) can be separated and detected, and two isomeric impurities (5E, 9E, 13Z), (5E, 9Z, 13E) and teprenone active ingredients can be separated and detected, thereby improving the efficiency, accuracy and sensitivity of analytical detection and reducing the detection cost.
[0008] One of the embodiments of the present specification provides a method for detecting related substances of teprenone, wherein the related substances of teprenone are detected by high performance liquid chromatography, and the chromatographic conditions of the high performance liquid chromatography include: a C30 chromatographic column, and a mobile phase of a mixed solution of acetonitrile, an alcohol solvent and water.
[0009] In some embodiments, the content of related substances of teprenone is calculated using area normalization method.
[0010] In some embodiments, the alcohol solvent comprises at least one of propanol, sec-butanol, tert-butanol and n-butanol. In some embodiments, the alcohol solvent preferably comprises n-butanol.
[0011] In some embodiments, the alcohol solvent is n-butanol, and the volume ratio of the mobile phase is [acetonitrile-n-butanol (2-3: 0.5-1)]-water (65-80: 20-35), [acetonitrile-n-butanol (2-3: 0.5-1)]-water (65-75: 25-35), [acetonitrile-n-butanol (2-3: 0.5-1)]-water (70-75: 25-30), [acetonitrile-n-butanol [acetonitrile-n-butanol (2.5: 1)]-water (69-73: 27-31), [acetonitrile-n-butanol (2.5: 1)]-water (69-71: 29-31), or any single value or subrange therein. In some embodiments, the alcohol solvent is n-butanol, and the volume ratio of the mobile phase is preferably [acetonitrile-n-butanol (2.5: 1)]-water (69-75: 25-31), preferably [acetonitrile-n-butanol (2.5: 1)]-water (69-73: 27-31), and more preferably [acetonitrile-n-butanol (2.5: 1)]-water (69-71: 29-31).
[0012] In some embodiments, the species of interest includes at least one epoxy impurity.
[0013] In some embodiments, the related substances include teprenone mono-cis isomers 5E, 9E, 13Z and teprenone mono-cis isomers 5E, 9Z, 13E. Teprenone mono-cis isomers 5E, 9E, 13Z and teprenone mono-cis isomers 5E, 9Z, 13E can achieve peak separation and be qualitatively identified.
[0014] In some embodiments, the active ingredient of teprenone includes mono-cis isomers 5Z, 9E, 13E and all-trans isomers 5E, 9E, 13E. In some embodiments, the separation degree of mono-cis isomers 5Z, 9E, 13E and all-trans isomers 5E, 9E, 13E is ≥ 1.5. In some embodiments, the separation degree of mono-cis isomers 5Z, 9E, 13E and all-trans isomers 5E, 9E, 13E is ≥ 1.8. In some embodiments, the separation degree of mono-cis isomers 5Z, 9E, 13E and all-trans isomers 5E, 9E, 13E is ≥ 2.0. In some embodiments, the separation degree of mono-cis isomers 5Z, 9E, 13E and all-trans isomers 5E, 9E, 13E is ≥ 2.3. In some embodiments, the resolution of the mono-cis isomers 5Z, 9E, 13E and the all-trans isomers 5E, 9E, 13E is ≥ 2.5. In some embodiments, the resolution of the mono-cis isomers 5Z, 9E, 13E and the all-trans isomers 5E, 9E, 13E is ≥ 2.6.
[0015] In some embodiments, the separation degree of the mono-cis isomers 5Z, 9E, 13E from the mono-cis isomers 5E, 9E, 13Z is ≥ 1.0. In some embodiments, the separation degree of the mono-cis isomers 5Z, 9E, 13E from the mono-cis isomers 5E, 9E, 13Z is ≥ 1.1. In some embodiments, the separation degree of the mono-cis isomers 5Z, 9E, 13E from the mono-cis isomers 5E, 9E, 13Z is ≥ 1.2. In some embodiments, the separation degree of the mono-cis isomers 5Z, 9E, 13E from the mono-cis isomers 5E, 9E, 13Z is ≥ 1.3. In some embodiments, the separation degree of the mono-cis isomers 5Z, 9E, 13E from the mono-cis isomers 5E, 9E, 13Z is ≥ 1.4. In some embodiments, the resolution of the mono-cis isomers 5Z, 9E, 13E and the mono-cis isomers 5E, 9E, 13Z is ≥ 1.5.
[0016] In some embodiments, the HPLC instrument comprises a Shimadzu HPLC instrument.
[0017] In some embodiments, the HPLC conditions are: Chromatographic column: triacontylsilane bonded silica gel is used as filler; Chromatographic column model: 4.6×250mm, 3μm; Mobile phase: a mixed solution of acetonitrile, alcohol solvent and water; Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 60-100min; Column temperature: 15°C; Injection volume: 10 μL.
[0018] In some embodiments, the running time of the chromatography includes 60-100min, 60-90min, 60-80min, 60-70min, 70-100min, 80-100min, 90-100min, or any single value or sub-range therein. For relevant contents about alcohol solvents, please refer to the description of other parts of this disclosure.
[0019] One of the embodiments of the present specification provides a teprenone bulk drug, and the related substances of teprenone in the teprenone bulk drug are detected using the detection method described in any embodiment of the present specification.
[0020] One of the embodiments of the present specification provides a teprenone preparation, and the related substances of teprenone in the teprenone preparation are detected using the detection method described in any embodiment of the present specification.
[0021] The beneficial effects that may be brought about by the embodiments of this specification include but are not limited to: (1) By using a chromatographic column filled with triacontylsilane bonded silica gel and a mobile phase having a volume ratio of [acetonitrile-n-butanol (2-3:0.5-1)]-water (65-80:20-35), epoxy impurities and isomeric impurities can be detected simultaneously, and two isomeric impurities (5E, 9E, 13Z) and (5E, 9Z, 13E) can be separated and detected, as well as two isomeric impurities (5E, 9E, 13Z), (5E, 9Z, 13E) and teprenone active ingredients can be separated and detected, thereby improving the efficiency, accuracy and sensitivity of the analysis and detection and reducing the detection cost. (2) By using a chromatographic column filled with triacontylsilane bonded silica gel and a mobile phase having a volume ratio of [acetonitrile-n-butanol (2-3:0.5-1)]-water (65-80:20-35), the operating time of the high performance liquid chromatography is shortened, the analytical detection efficiency, accuracy and sensitivity of the detection method are improved, and the detection cost is reduced while ensuring a high degree of separation between the active ingredient of teprenone and the isomeric impurities.
[0022] It should be noted that different embodiments may produce different beneficial effects. In different embodiments, the beneficial effects that may be produced may be any one or a combination of the above, or any other beneficial effects that may be obtained. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The present specification will be further illustrated by means of exemplary embodiments, which will be described in detail through the accompanying drawings.
[0024] Figure 1 It is a liquid chromatogram of Example 1 shown in some embodiments of this specification.
[0025] Figure 2 It is a liquid chromatogram of Example 6 shown in some embodiments of this specification.
[0026] Figure 3 is a liquid chromatogram of exemplary epoxy impurities according to some embodiments of the present specification.
[0027] Figure 4 is a liquid chromatogram of exemplary epoxy impurities and isomeric impurities according to some examples of the present specification.
[0028] Figure 5 It is an overlay diagram of the specificity test results of each solution according to some embodiments of this specification. DETAILED DESCRIPTION
[0029] In order to more clearly illustrate the technical solution of the present invention, the technical solution of the present invention will be described using embodiments below. It should be understood that the description of the embodiments is only for the convenience of understanding the technical solution, rather than limiting the present invention to the specific embodiments shown. The titles in this application are provided only for convenience and should not be interpreted as limiting the present invention in any way. The embodiments shown under any title can be combined with the embodiments shown under any other title. For those of ordinary skill in the art, various modifications, improvements and amendments can also be made to these embodiments without paying creative work. So such modifications, improvements and amendments still belong to the spirit and scope of the exemplary embodiments of this specification.
[0030] In the present invention, one of the active ingredients of teprenone, "5Z, 9E, 13E", can be expressed in the form of "(5Z, 9E, 13E)", "(ZEE)" or "ZEE", and these four representations all represent the same substance, namely, one of the active ingredients "5Z, 9E, 13E". Similarly, another active ingredient 5E, 9E, 13E and the remaining six isomeric impurities can also be expressed in similar forms, and the four representations of the same isomer can be used to represent the structure of the isomer.
[0031] In the present invention, "separation" and "substantially separation" generally refer to the separation of two peaks ≥ 1.0 or baseline separation. In the present invention, "detection" generally refers to the qualitative identification and quantitative detection of components, wherein quantitative detection can be the quantification of a single component or the quantification of multiple components in combination.
[0032] In order to improve the analytical detection efficiency, accuracy and sensitivity of the high performance liquid chromatography detection method, the applicant has conducted long-term, multi-faceted attempts and experiments, and found that by using a chromatographic column with triacontylsilane bonded silica gel as a filler and a mobile phase volume ratio of [acetonitrile-n-butanol (2-3:0.5-1)]-water (65-80:20-35), epoxy impurities and isomeric impurities can be detected simultaneously, and two isomeric impurities (5E, 9E, 13Z) and (5E, 9Z, 13E) can be detected, as well as two isomeric impurities (5E, 9E, 13Z), (5E, 9Z, 13E) and teprenone active ingredients, thereby improving the analytical detection efficiency and reducing the detection cost; and under the premise of ensuring a high degree of separation between the teprenone active ingredient and the isomeric impurities, the running time of the high performance liquid chromatography can be shortened, the analytical detection efficiency, accuracy and sensitivity of the detection method can be improved, and the detection cost can be reduced, which to a certain extent reflects the progress of the detection method and the improvement of economic benefits.
[0033] The present disclosure provides a method for detecting related substances of teprenone. In some embodiments, the related substances of teprenone can be detected by high performance liquid chromatography, and the chromatographic conditions of the high performance liquid chromatography include: a C30 chromatographic column, and a mobile phase of a mixed solution of acetonitrile, an alcohol solvent and water.
[0034] In some embodiments, the content of related substances of teprenone is calculated using area normalization method.
[0035] In some embodiments, the alcohol solvent comprises at least one of propanol, sec-butanol, tert-butanol and n-butanol. In some embodiments, the alcohol solvent preferably comprises n-butanol.
[0036] In some embodiments, the alcohol solvent is n-butanol, and the volume ratio of the mobile phase is [acetonitrile-n-butanol (2-3: 0.5-1)]-water (65-80: 20-35), [acetonitrile-n-butanol (2-3: 0.5-1)]-water (65-75: 25-35), [acetonitrile-n-butanol (2-3: 0.5-1)]-water (70-75: 25-30), [acetonitrile-n-butanol [acetonitrile-n-butanol (2.5: 1)]-water (69-73: 27-31), [acetonitrile-n-butanol (2.5: 1)]-water (69-71: 29-31), or any single value or subrange therein. In some embodiments, the alcohol solvent is n-butanol, and the volume ratio of the mobile phase is preferably [acetonitrile-n-butanol (2.5: 1)]-water (69-75: 25-31), preferably [acetonitrile-n-butanol (2.5: 1)]-water (69-73: 27-31), and more preferably [acetonitrile-n-butanol (2.5: 1)]-water (69-71: 29-31).
[0037] In some embodiments, the related substance includes at least one epoxy impurity. The structure of the epoxy impurity can be referred to the description of the background art.
[0038] In some embodiments, the related substances include teprenone mono-cis isomers 5E, 9E, 13Z and teprenone mono-cis isomers 5E, 9Z, 13E. Teprenone mono-cis isomers 5E, 9E, 13Z and teprenone mono-cis isomers 5E, 9Z, 13E can achieve peak separation and be qualitatively identified.
[0039] In some embodiments, the active ingredient of teprenone includes mono-cis isomers 5Z, 9E, 13E and all-trans isomers 5E, 9E, 13E. In some embodiments, the separation degree of mono-cis isomers 5Z, 9E, 13E and all-trans isomers 5E, 9E, 13E is ≥ 1.5. In some embodiments, an appropriate amount of teprenone bulk drug is taken, and appropriate amounts of each epoxy impurity, impurity EZE, impurity EEZ and impurity ZZE reference substance are added, and the solution is dissolved and diluted with acetonitrile to prepare a spiked test solution.
[0040] In some embodiments, the HPLC instrument comprises a Shimadzu HPLC instrument.
[0041] In some embodiments, the HPLC conditions are:
[0042] Chromatographic column: triacontylsilane bonded silica gel is used as filler; Chromatographic column model: 4.6×250mm, 3μm; Mobile phase: a mixed solution of acetonitrile, alcohol solvent and water; Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 60-100min; Column temperature: 15°C; Injection volume: 10 μL.
[0043] In some embodiments, the run time of the chromatography comprises 60-100 min, 60-90 min, 60-80 min, 60-70 min, 70-100 min, 80-100 min, 90-100 min, or any single value or subrange therein.
[0044] The present disclosure provides a teprenone bulk drug, and the related substances of teprenone in the teprenone bulk drug are detected using the detection method described in any embodiment of the specification.
[0045] The present disclosure provides a teprenone preparation, and the related substances of teprenone in the teprenone preparation are detected using the detection method described in any embodiment of the present specification.
[0046] In some embodiments, the teprenone preparation may include at least one of capsules, granules, tablets, and powders of teprenone. Example:
[0047] Specific embodiments of the present disclosure will now be described with reference to the following examples. It should be understood that these examples are disclosed only by way of illustration of the present disclosure and should not be used to limit the scope of the present disclosure in any way. Comparative Example 1:
[0048] (1) Preparation of test solution
[0049] Take an appropriate amount of teprenone bulk drug and quantitatively dilute it with acetonitrile to prepare a solution containing about 0.5 mg per 1 ml.
[0050] (2) Preparation of reference solution
[0051] Take an appropriate amount of teprenone reference substance, weigh it accurately, dissolve it in acetonitrile and quantitatively dilute it to make a solution containing about 1 μg per 1 ml.
[0052] (3) Preparation of spiked test solution
[0053] Take appropriate amounts of teprenone, isomeric impurity EZE and EEZ reference substance, dissolve and dilute with acetonitrile to prepare a mixed solution containing approximately 0.5 mg of teprenone and 2.5 μg of each impurity per 1 ml.
[0054] (4) Sample testing
[0055] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0056] The chromatographic conditions of the HPLC were: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: octadecylsilane bonded silica gel as filler; Chromatographic column model: Agilent HPH-C18, 2.1×100mm, 2.7μm; Mobile phase: acetonitrile and water in a 50:50 volume ratio; Flow rate: 0.5 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 100min; Column temperature: 30°C; Injection volume: 10 μL. Comparative Example 2:
[0057] According to the description of patent CN116539765B, paragraphs
[0074] -
[0087] :
[0058] The HPLC conditions were: Instruments: SHIMADZU high performance liquid chromatograph, Waters high performance liquid chromatograph; Chromatographic column: The filler is silica gel coated with amylose-tris-(3,5-dimethylphenylcarbamate). The column model is Chiralpak AD-RH, 4.6×250 mm, 5 μm; Mobile phase: a mixed solution of acetonitrile and water, with a volume ratio of acetonitrile to water of 65:35; Flow rate: 1.0 mL / min; The detector is an ultraviolet detector, wavelength: 210nm; Running time: 180min; Column temperature: 30°C; Injection volume: 20 μL.
[0059] The peaks of target impurities (EZE, EEZ) are difficult to separate from each other and basically overlap into one peak, so the two target impurities are combined for calculation. Comparative Example 3:
[0060] The preparation methods of the test solution, the reference solution and the spiked test solution are carried out according to the steps (1) to (3) in Comparative Example 1.
[0061] (4) Sample testing
[0062] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0063] The chromatographic conditions of the HPLC were: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: triacontylsilane bonded silica gel is used as filler; Column model: Welch Ultimate XB-C30, 4.6×250 mm, 3 μm; Mobile phase: acetonitrile and water in a volume ratio of 90:10; Flow rate: 1.0 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 60min; Column temperature: 30°C; Injection volume: 10 μL. Comparative Example 4:
[0064] The preparation methods of the test solution, the reference solution and the spiked test solution are carried out according to the steps (1) to (3) in Comparative Example 1.
[0065] (4) Sample testing
[0066] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0067] The chromatographic conditions of the HPLC were: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: triacontylsilane bonded silica gel is used as filler; Column model: Welch Ultimate XB-C30, 4.6×250 mm, 3 μm; Mobile phase: acetonitrile, methanol and water, volume ratio: [acetonitrile-methanol (2:1)]-water (90:10); Flow rate: 1.0 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 60min; Column temperature: 15°C; Injection volume: 10 μL. Embodiment 1:
[0068] The preparation methods of the test solution, the reference solution and the spiked test solution are carried out according to the steps (1) to (3) in Comparative Example 1.
[0069] (4) Sample testing
[0070] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0071] The chromatographic conditions of the HPLC were: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: triacontylsilane bonded silica gel is used as filler; Column model: Welch Ultimate XB-C30, 4.6×250 mm, 3 μm; Mobile phase: acetonitrile, n-butanol and water, volume ratio: [acetonitrile-n-butanol (2:1)]-water (80:20); Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 60min; Column temperature: 15°C; Injection volume: 10 μL. Embodiment 2:
[0072] The preparation methods of the test solution, the reference solution and the spiked test solution are carried out according to the steps (1) to (3) in Comparative Example 1.
[0073] (4) Sample testing
[0074] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0075] The chromatographic conditions of the HPLC were: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: triacontylsilane bonded silica gel is used as filler; Column model: Welch Ultimate XB-C30, 4.6×250 mm, 3 μm; Mobile phase: acetonitrile, n-butanol and water, volume ratio: [acetonitrile-n-butanol (3:1)]-water (80:20); Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 60min; Column temperature: 15°C; Injection volume: 10 μL. Embodiment 3:
[0076] The preparation methods of the test solution, the reference solution and the spiked test solution are carried out according to the steps (1) to (3) in Comparative Example 1.
[0077] (4) Sample testing
[0078] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0079] The chromatographic conditions of the HPLC were: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: triacontylsilane bonded silica gel is used as filler; Column model: Welch Ultimate XB-C30, 4.6×250 mm, 3 μm; Mobile phase: acetonitrile, n-butanol and water, volume ratio: [acetonitrile-n-butanol (2.5:1)]-water (75:25); Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 60min; Column temperature: 15°C; Injection volume: 10 μL. Embodiment 4:
[0080] The preparation methods of the test solution, the reference solution and the spiked test solution are carried out according to the steps (1) to (3) in Comparative Example 1.
[0081] (4) Sample testing
[0082] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0083] The chromatographic conditions of the HPLC were: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: triacontylsilane bonded silica gel is used as filler; Column model: Welch Ultimate XB-C30, 4.6×250 mm, 3 μm; Mobile phase: acetonitrile, n-butanol and water, volume ratio: [acetonitrile-n-butanol (2.5:1)]-water (73:27); Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 80min; Column temperature: 15°C; Injection volume: 10 μL. Embodiment 5:
[0084] The preparation methods of the test solution, the reference solution and the spiked test solution are carried out according to the steps (1) to (3) in Comparative Example 1.
[0085] (4) Sample testing
[0086] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0087] The chromatographic conditions of the HPLC were: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: triacontylsilane bonded silica gel is used as filler; Column model: Welch Ultimate XB-C30, 4.6×250 mm, 3 μm; Mobile phase: acetonitrile, n-butanol and water, volume ratio: [acetonitrile-n-butanol (2.5:1)]-water (71:29); Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 100min; Column temperature: 15°C; Injection volume: 10 μL. Embodiment 6:
[0088] The preparation methods of the test solution, the reference solution and the spiked test solution are carried out according to the steps (1) to (3) in Comparative Example 1.
[0089] (4) Sample testing
[0090] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0091] The chromatographic conditions of the HPLC were: Mobile phase: acetonitrile, n-butanol and water, volume ratio: [acetonitrile-n-butanol (2.5:1)]-water (69:31); The remaining chromatographic conditions are the same as those in Example 5.
[0092] The test results of Comparative Examples 1-4 and Examples 1-6 are shown in Table 1, and the chromatograms of Examples 1 and 6 are shown in Figure 1-2 shown.
[0093] The experimental results show that: (1) using a chromatographic column C30, 4.6×250mm, 3μm, flow rate: 0.8mL / min; column temperature: 15℃; injection volume: 10μL; wavelength: 210nm; the volume ratio of the mobile phase is [acetonitrile-n-butanol (2-3:0.5-1)]-water (65-80:20-35); running time: 60-100min, the isomeric impurities EZE and EEZ of teprenone can be separated and identified, and the two main peaks are completely separated and can be detected. (2) Using a chromatographic column C30, 4.6×250 mm, 3 μm, flow rate: 0.8 mL / min; column temperature: 15°C; injection volume: 10 μL; wavelength: 210 nm; the volume ratio of the mobile phase is [acetonitrile-n-butanol (2.5:1)]-water (69-75:25-31); running time: 60-100 min, the isomeric impurities EZE and EEZ of teprenone can be separated and detected, the main peak ZEE and the isomeric impurity EEZ are completely separated, and the two main peaks are completely separated and can be detected. The above chromatographic detection method shortens the chromatographic running time, improves the analytical detection efficiency, accuracy and sensitivity of the detection method, and reduces the detection cost while ensuring a high degree of separation between the isomeric impurities of teprenone and the isomeric impurities and the active ingredient. Embodiment 7:
[0094] (1) Preparation of test solution
[0095] Take an appropriate amount of teprenone bulk drug and quantitatively dilute it with acetonitrile to prepare a solution containing about 0.5 mg per 1 ml.
[0096] (2) Preparation of reference solution
[0097] Take an appropriate amount of teprenone reference substance, weigh it accurately, dissolve it in acetonitrile and quantitatively dilute it to make a solution containing about 1 μg per 1 ml.
[0098] (3) Preparation of spiked test solution
[0099] Take appropriate amounts of teprenone bulk drug, isomeric impurities EZE, ZZE and EEZ, and epoxy impurity reference substance, dissolve and dilute with acetonitrile to prepare a mixed solution containing approximately 0.5 mg of teprenone and 1 μg of each impurity per 1 ml.
[0100] (4) Sample testing
[0101] Same as Example 5.
[0102] The test results of Example 7 are as follows Figure 3 shown.
[0103] The experimental results show that the seven epoxy impurities of teprenone can also be separated and detected using the same liquid chromatography conditions as those for detecting isomeric impurities mentioned above. There is no need to establish separate detection standards for epoxy impurities and isomeric impurities, which improves the analytical detection efficiency, accuracy and sensitivity of the high performance liquid chromatography method and reduces the detection cost. Embodiment 8:
[0104] (1) Preparation of test solution
[0105] Take an appropriate amount of teprenone bulk drug and quantitatively dilute it with acetonitrile to prepare a solution containing about 0.5 mg per 1 ml.
[0106] (2) Preparation of reference solution
[0107] Take an appropriate amount of teprenone reference substance, weigh it accurately, dissolve it in acetonitrile and quantitatively dilute it to make a solution containing about 1 μg per 1 ml.
[0108] (3) Preparation of spiked test solution
[0109] Take appropriate amounts of teprenone bulk drug, isomeric impurities EZE, ZZE and EEZ, and epoxy impurity reference substance, dissolve and dilute with acetonitrile to prepare a mixed solution containing approximately 0.5 mg of teprenone and 1 μg of each impurity per 1 ml.
[0110] (4) Sample testing
[0111] Same as Example 5.
[0112] The test results of Example 8 are as follows Figure 4 shown.
[0113] The experimental results show that the liquid chromatography conditions of Example 5 can not only separate the epoxy impurities and isomeric impurities of teprenone, but also separate and detect two isomeric impurities (5E, 9E, 13Z) and (5E, 9Z, 13E), and at the same time, the two mono-cis isomeric impurities (5E, 9E, 13Z) and (5E, 9Z, 13E) can be separated and detected from the teprenone active ingredients 5Z, 9E, 13E and 5E, 9E, 13E, thereby improving the analytical detection efficiency, accuracy and sensitivity of the high performance liquid chromatography and reducing the detection cost. Example 9: Methodological Validation
[0114] The methods of teprenone raw materials and teprenone preparations were validated with reference to the 9101 Analytical Method Validation Guidelines of Part IV of the 2020 Edition of the Chinese Pharmacopoeia.
[0115] 9.1. Exclusivity
[0116] The specific information of reagents and instruments used in the examples of the present invention are as follows:
[0117] (1) Blank solution: acetonitrile.
[0118] (2) Reference solution: Take an appropriate amount of teprenone reference substance, accurately weigh it, dissolve it in acetonitrile and quantitatively dilute it to make a solution containing approximately 2.5 μg per 1 mL.
[0119] (3) Epoxy impurity localization solution: Take about 0.25 g of teprenone API, place it in a 25 ml volumetric flask, add an appropriate amount of acetonitrile to dissolve it, add an appropriate amount of hydrogen peroxide solution, and dilute to the mark with acetonitrile to serve as the localization stock solution. Take the solution, heat and reflux in a 70°C water bath for 2 hours, cool it, take 1 ml, place it in a 100 ml volumetric flask, dilute to the mark with acetonitrile, and shake well to obtain the localization stock solution.
[0120] (4) Mixed solution of other impurities: Take impurities other than isomer impurity EZE, impurity EEZ and epoxy impurity, dissolve them in acetonitrile and dilute them to make a solution containing about 2.5 μg of each impurity per 1 mL.
[0121] (5) System suitability solution: Take appropriate amounts of teprenone, impurity EZE, impurity ZZE and impurity EEZ reference substances, dissolve them in acetonitrile and dilute them to prepare a mixed solution containing approximately 0.5 mg of teprenone and 2.5 μg of each impurity per 1 mL.
[0122] (6) Test solution: Take an appropriate amount of teprenone bulk drug and quantitatively dilute it with acetonitrile to make a solution containing approximately 0.5 mg per 1 ml.
[0123] (7) Spiked test solution: Take an appropriate amount of teprenone API and add appropriate amounts of Epoxy Impurity 1, Epoxy Impurity 2, Epoxy Impurity 3, Epoxy Impurity 4, Impurity EZE, Impurity EEZ and Impurity ZZE reference substances. Dissolve and dilute with acetonitrile to prepare a mixed solution containing approximately 0.5 mg of teprenone and 1 μg of each impurity per 1 mL.
[0124] (8) HPLC conditions: Instrument: Shimadzu high performance liquid chromatograph; Chromatographic column: triacontylsilane bonded silica gel is used as filler; Column model: Welch Ultimate XB-C30, 4.6×250 mm, 3 μm; Mobile phase: a mixed solution of acetonitrile, n-butanol and water, with a volume ratio of [acetonitrile-n-butanol (2.5:1)]-water (71:29); Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 80min; Column temperature: 15°C; Injection volume: 10 μL.
[0125] Specificity investigation: blank solution, reference solution, epoxy impurity location solution, other impurity mixed solution, system suitability solution, test solution, and spiked test solution were sampled and tested respectively to investigate the specificity of the method. The specificity results are shown in Table 2 and Figure 5 . Table 2 Specificity results
[0126] From Table 2 and Figure 5 It can be seen that the detection method can detect and identify epoxy impurities and isomeric impurities at the same time, without the need to establish separate detection standards for epoxy impurities and isomeric impurities, thereby improving the efficiency of analysis and detection and reducing the detection cost. In addition, the minimum separation between the isomeric impurity EZE peak and the impurity EEZ peak is 0.96, and the minimum separation between the impurity EEZ peak and the monocis isomer ZEE peak is 1.55. In a short running time, the main peak and the isomeric impurities can be completely separated, and the isomeric impurities EZE and EEZ can be separated and identified, indicating that the method has good specificity.
[0127] 9.2 Limit of Quantitation and Limit of Detection
[0128] HPLC conditions: Same as those in Example “9.1. Specificity”.
[0129] Take appropriate amounts of teprenone, isomeric impurity EZE, isomeric impurity EEZ, and epoxy impurity, prepare them into appropriate concentrations with acetonitrile, inject and measure, take the lowest concentration point with signal-to-noise ratio S / N ≥ 10 as the quantitative limit, take the lowest concentration point with signal-to-noise ratio S / N ≥ 3 as the detection limit, and examine the sensitivity of the method. The results are shown in Table 3. Table 3 Results of limit of quantitation and limit of detection
[0130] The results showed that the limit of quantification of the mono-cis isomer ZEE of teprenone was 0.1 μg / mL, the limit of quantification of the all-trans isomer EEE of teprenone was 0.1 μg / mL, the limit of quantification of the isomeric impurity EZE was 0.07 μg / mL, the limit of quantification of the isomeric impurity EEZ was 0.1 μg / mL, the limit of quantification of the epoxy impurity 1 and epoxy impurity 2 was 0.05 μg / mL, and the limit of quantification of the epoxy impurity 3 and epoxy impurity 4 was 0.1 μg / mL.
[0131] 9.3 Linear Relationship
[0132] HPLC conditions: Same as those in Example “9.1. Specificity”.
[0133] Take appropriate amount of teprenone, isomer impurity EZE, isomer impurity EEZ, and epoxy impurity, quantitatively dilute with acetonitrile to prepare a series of reference solutions, inject samples separately, and examine the correlation with linear equation and correlation coefficient. The linear concentration range is from 0.25 to 2μg / ml, and the linear range is equivalent to 25%-200% of the limit concentration range. Verification standard: The linear correlation coefficient between concentration and main peak area should be greater than 0.999, and the intercept should be within 25% of the 100% concentration response value.
[0134] From the results of the linear relationship investigation, it can be seen that the linear correlation coefficient of the active ingredient of teprenone, isomeric impurity EZE, isomeric impurity EEZ, and epoxy impurity 1 to epoxy impurity 4 in the concentration range of 0.25 to 2 μg / mL is r>0.999, and the linear relationship is good.
[0135] 9.4 Precision
[0136] HPLC conditions: Same as those in Example “9.1. Specificity”.
[0137] (1) Repeatability
[0138] Take appropriate amounts of teprenone bulk drug, isomeric impurity EZE, isomeric impurity EEZ and epoxy impurity to prepare spiked test solutions containing the limit concentration of each impurity, and prepare 6 copies in parallel. At the same time, prepare reference solution, inject and measure separately, and examine the repeatability of the method by the RSD of impurity content. The verification standard is RSD%≤3%. The results are shown in Table 4. Table 4 Repeatability test results
[0139] As can be seen from Table 4, in the 6 test solutions, the maximum RSD of the impurity content was 2.38% (isomer impurity EZE), and the repeatability met the requirements, indicating that the method had good repeatability.
[0140] (2) Intermediate precision
[0141] Different experimenters, on different dates or with different instruments, took appropriate amounts of teprenone, isomeric impurity EZE, isomeric impurity EEZ and epoxy impurity, repeated the "repeatability" test, and analyzed and compared them with the "repeatability" test results in Table 4. The verification standard was RSD%≤6%. The results are shown in Table 5. Table 5 Intermediate precision test results
[0142] As can be seen from Table 5, in the 6 test solutions, the maximum RSD of the impurity content was 3.63% (isomer impurity EZE), and the intermediate precision met the requirements, indicating that the method had good repeatability.
[0143] In summary, the results of Examples 9.1-9.4 show that the method for detecting related substances of teprenone (epoxy impurities and isomeric impurities EZE, EEZ) provided by the present invention can simultaneously detect epoxy impurities and isomeric impurities, and can separate and detect two isomeric impurities (5E, 9E, 13Z) and (5E, 9Z, 13E), as well as separate and detect two isomeric impurities (5E, 9E, 13Z), (5E, 9Z, 13E) and teprenone active ingredients, thereby improving the efficiency, accuracy and sensitivity of analysis and detection, and reducing the detection cost; and the chromatographic running time is short, the separation is good, the specificity is good, the linear relationship is good, the precision is high and the durability is good, which is suitable for the identification and detection of related substances in teprenone raw materials and teprenone preparations.
[0144] As used in this disclosure, "about" refers to any value within a variation of ±5-20%, such that "about 10" would include values within the range of 8 to 12. Unless otherwise indicated herein, recitation of ranges of values in this disclosure is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, and each separate value is incorporated into the specification as if it were individually recited in this disclosure. All methods described herein can be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context.
[0145] The use of any and all examples or exemplary language provided in this disclosure is intended merely to illustrate certain materials and methods and does not limit the scope. No language in the specification should be construed as indicating any non-claimed element as essential to practice the disclosed materials and methods.
[0146] As shown in the present disclosure and claims, unless the context clearly indicates an exception, the words "a", "an", "an" and / or "the" do not refer to the singular and may also include the plural. Generally speaking, the terms "include" and "comprise" only indicate the inclusion of the steps and elements that have been clearly identified, and these steps and elements do not constitute an exclusive list. The method or composition may also include other steps or elements.
[0147] At the same time, this specification uses specific words to describe the embodiments of this specification. For example, "in some embodiments", "in various embodiments", "one embodiment", "an embodiment", and / or "some embodiments" refer to a certain feature, structure or characteristic related to at least one embodiment of this specification. Therefore, it should be emphasized and noted that "in some embodiments", "in various embodiments", "one embodiment", "an embodiment", and / or "some embodiments" mentioned twice or more in different positions in this specification do not necessarily refer to the same embodiment. In addition, some features, structures or characteristics in one or more embodiments of this specification can be appropriately combined.
[0148] Although the above disclosure discusses some of the invention embodiments currently considered useful through various examples, it should be understood that such details are only for illustrative purposes, and the appended claims are not limited to the disclosed embodiments. On the contrary, the claims are intended to cover all modifications and equivalent combinations that are consistent with the essence and scope of the embodiments of this specification.
[0149] Similarly, it should be noted that in order to simplify the description disclosed in this specification and thus help understand one or more embodiments of the invention, in the description of the embodiments of this specification, multiple features are sometimes combined into one embodiment. However, this disclosure method does not mean that the features required by the subject matter of this specification are more than the features mentioned in the claims.
[0150] Finally, it should be understood that the embodiments described in this specification are only used to illustrate the principles of the embodiments of this specification. Other variations may also fall within the scope of this specification. Therefore, as an example and not a limitation, alternative compositions of the embodiments of this specification may be considered consistent with the teachings of this specification. Accordingly, the embodiments of this specification are not limited to the embodiments explicitly introduced and described in this specification.
Claims
1. A method for detecting related substances of teprenone, characterized in that, The related substances of the teprenone were detected by high performance liquid chromatography, wherein: The chromatographic conditions of the high performance liquid chromatography include: Chromatographic column: triacontylsilane bonded silica gel is used as filler, Mobile phase: a mixture of acetonitrile, alcohol solvent and water.
2. The detection method according to claim 1, characterized in that The chromatographic conditions of the high performance liquid chromatography include: Chromatographic column: triacontylsilane bonded silica gel is used as filler; Chromatographic column model: 4.6×250mm, 3μm; Mobile phase: a mixed solution of acetonitrile, alcohol solvent and water; Flow rate: 0.8 mL / min; Detector: UV detector, wavelength: 210nm; Running time: 60-100min; Column temperature: 15°C; Injection volume: 10 μL.
3. The detection method according to claim 1 or 2, characterized in that: The alcohol solvent includes at least one of propanol, sec-butanol, tert-butanol and n-butanol.
4. The detection method according to claim 1 or 2, characterized in that: The alcohol solvent includes n-butanol, and the volume ratio of the mobile phase is [acetonitrile-n-butanol (2-3: 0.5-1)]-water (65-80: 20-35), preferably [acetonitrile-n-butanol (2-3: 0.5-1)]-water (65-75: 25-35), preferably [acetonitrile-n-butanol (2-3: 0.5-1)]-water (70-75: 25-30), preferably [acetonitrile-n-butanol (2-3: 0.5-1)]-water (70-75: 25-30). Nitrile-n-butanol (2-2.5:0.5-1)]-water (70-75:25-30), preferably [acetonitrile-n-butanol (2.5:1)]-water (69-75:25-31), preferably [acetonitrile-n-butanol (2.5:1)]-water (69-73:27-31), more preferably [acetonitrile-n-butanol (2.5:1)]-water (69-71:29-31).
5. The detection method according to claim 1, characterized in that The related substances include at least one epoxy impurity.
6. The detection method according to claim 1, characterized in that The related substances also include teprenone mono-cis isomers 5E, 9E, 13Z and teprenone mono-cis isomers 5E, 9Z, 13E.
7. The detection method according to claim 6, characterized in that The active ingredients of teprenone include mono-cis isomers 5Z, 9E, 13E and all-trans isomers 5E, 9E, 13E, and the separation degree between the mono-cis isomers 5Z, 9E, 13E and the mono-cis isomers 5E, 9E, 13Z is ≥1.
0.
8. A teprenone bulk drug, characterized in that: The related substances of teprenone in the teprenone bulk drug are detected using the detection method described in any one of claims 1 to 7.
9. A teprenone preparation, characterized in that: The related substances of teprenone in the teprenone preparation are detected using the detection method according to any one of claims 1 to 7.
Citation Information
Patent Citations
A method for detecting related substances in teprenone capsules
CN116539765B
Cited By
Detection method of teprenone
CN119375409A
